Business

Exmoor Pharma CEO Lucy Foley says manufacturing is only part of reaching patients

· 1 source · Ireland edition

This story has no audio yet

Lucy Foley, chief executive of cell and gene therapy manufacturer Exmoor Pharma, worked in a local pharmacy at 13, where the pharmacist taught her how medicines worked. She told SiliconRepublic.com this showed her that medicine offered careers beyond becoming a doctor. She later chose biochemical engineering at UCL, where she could study biology.

Foley previously helped establish the National Biologics Manufacturing Centre in the UK and later led the RNA Centre of Excellence during the Covid-19 pandemic. She called the work fast and, at times, scary, yet one of the most rewarding things she had done. It showed her that manufacturing is only one part of getting a drug to patients.

Foley said one-off cell and gene therapies, which can offer a lifetime of benefit, raise questions about how medicines are paid for. She said automation is badly needed to industrialise production, and that AI and machine learning are underused. Her main concern, she said, is greater patient access to critical medicines through higher volumes and lower cost while maintaining quality.

Key points

  • Lucy Foley, CEO of Exmoor Pharma, worked in a local pharmacy at 13, where she learned how medicines worked.
  • Her work on the RNA Centre of Excellence during the Covid-19 pandemic showed her that manufacturing is only one part of reaching patients.
  • Foley said cell and gene therapies, which can offer a lifetime of benefit, raise questions about how medicines are paid for.
  • She said the industry must scale up to treat thousands of patients, not hundreds.
  • Her main concern, she said, is greater patient access to critical medicines through higher volumes and lower cost.

Coverage from

Topics

This story was put together automatically from the sources above. Open a source to read its original report. How nuze makes stories